T-Cell Impurity Flow Cytometry Panel Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for T cell immunotherapy products face challenges in characterizing and quantifying non-T cell impurities like B cells, NK cells, and monocytes, which are essential for ensuring product quality and purity, especially during the manufacturing process.
Innovation Solution
Development of fit-for-purpose 2-8 color T-cell impurity flow cytometry panels that detect up to seven different blood cell surface markers, including a viability dye, to efficiently identify and quantify CD3− cellular impurities in lymphocyte-rich samples, eliminating the need for titrating antibody lots and reducing error-prone steps, while ensuring lot-to-lot consistency and streamlined workflow.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple markers are used to identify and characterize individual subsets of non-T cell impurities, then the accuracy of impurity characterization is improved, but the complexity of the flow cytometry panels and antibody titration procedures increases
Solution Approach 1:
The patent applies universality by designing flow cytometry panels where antibodies serve multiple functions: they detect specific cell surface markers (CD19 for B cells, CD14 for monocytes, CD56 for NK cells) while also enabling quantification through standardized fluorescent intensity measurements. The panels are configured to simultaneously detect multiple impurity types with a single assay, eliminating the need for separate titration procedures for each marker while maintaining accurate characterization of all non-T cell subsets.
2Adaptability or versatility
If traditional flow cytometry methods with antibody titration are used, then flexibility in detecting different markers is improved, but the time required for preparation and the potential for errors increase
Solution Approach 1:
The patent implements preliminary action by pre-configuring flow cytometry panels with optimized antibody concentrations and fluorescent labelings before use. The panels are prepared in advance with predetermined antibody lots that have been validated for consistent performance, eliminating the need for time-consuming titration experiments during each assay. This preliminary preparation maintains the ability to detect multiple markers while significantly reducing preparation time and minimizing opportunities for human error.
3Adaptability or versatility
If manual antibody titration and cocktail preparation steps are performed, then customization for different samples is improved, but the risk of pipetting errors and inconsistency between batches increases
Solution Approach 1:
The patent applies parameter changes by establishing standardized parameters for antibody concentrations, fluorescent labeling ratios, and panel configurations that are optimized for detecting multiple impurity types. These parameters are predetermined and validated to ensure consistent performance across different batches. The standardized parameters enable reliable quantification of B cells, monocytes, and NK cells while minimizing variability between experiments, achieving both sample adaptability and batch consistency through controlled parameter specifications.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution provides reliable and efficient characterization of impurities, ensuring the quality of T cell products by accurately detecting and quantifying CD3− cells at various stages of manufacturing, thereby improving the purity and efficacy of T cell immunotherapy.
Implementation Method 1
fluorescently-labeled antibodies as described in Tables 3, 4, and 5, using fluorescence detection methods
Data Source
AI summary
Compositions and methods for fluorescence activated cell analysis of blood cell populations.